Cristina Gasparetto, MD, associate professor, head of the myeloma program, Duke University Medical Center, discusses a phase 1b study to assess the combination of selinexor and daratumumab in patients with relapsed/refractory multiple myeloma previously exposed to proteasome inhibitors and immunomodulatory drugs during the 2017 ASH Annual Meeting.
Eftilagimod Alpha Added to Pembrolizumab Induces Hopeful Responses in Metastatic HNSCC
June 6th 2023Eftilagimod alpha plus pembrolizumab showed an overall response rate of over 25% in patients with metastatic head and neck squamous cell carcinoma treated in the phase 2 TACTI-002 study.
Read More
Niraparib Maintenance Therapy Induces Antitumor Activity in Advanced Ovarian Cancer
June 6th 2023The use of maintenance niraparib therapy led to clinically meaningful improvement in progression-free survival, compared with placebo, in patients with newly diagnosed, advanced ovarian cancer.
Read More
Axi-cel Significantly Reduces Risk of Death in Patients With R/R LBCL
June 6th 2023Treatment with axicabtagene ciloleucel in the second-line setting led to significant improvement in overall survival compared with high-dose therapy plus transplant in patients with early relapsed or refractory large B-cell lymphoma.
Read More
2 Clarke Drive
Cranbury, NJ 08512